PUBLISHER: The Business Research Company | PRODUCT CODE: 1763062
PUBLISHER: The Business Research Company | PRODUCT CODE: 1763062
Blincyto (blinatumomab) is a prescription medication designed for the treatment of specific blood cancers. As a bi-specific T-cell engager (BiTE) antibody construct, it operates by linking cancerous B-cells with T-cells (a type of immune cell), harnessing the immune system to identify and eliminate the cancerous B-cells.
Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
The primary types of blincyto are prefilled and non-prefilled formulations. The prefilled option comes in ready-to-use syringes or vials, simplifying preparation and administration. It is distributed through hospital pharmacies, retail pharmacies, and online pharmacies, and is used to treat acute lymphoblastic leukemia and other hematological disorders. Key users include hospitals, clinics, and research institutions.
The blincyto market research report is one of a series of new reports from The Business Research Company that provides blincyto market statistics, including blincyto industry global market size, regional shares, competitors with a blincyto market share, detailed blincyto market segments, market trends and opportunities, and any further data you may need to thrive in the blincyto industry. This blincyto market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The blincyto market size is expected to see strong growth in the next few years. It will grow to $1,022.1 million in 2029 at a compound annual growth rate (CAGR) of 6%. The growth in the forecast period can be attributed to increasing shift towards patient-centric care models, increasing availability of injectable therapies, increasing interest from pharmaceutical companies, increasing focus on quality of life improvements, rising incidence of ALL in adults. Major trends in the forecast period include research funding for technological advancements, emergence of bispecific t-cell engagers, advancements in cell therapy, enhanced patient monitoring technologies, improved formulation techniques.
The growing incidence of leukemia is anticipated to drive the expansion of the Blincyto market. Leukemia, a type of cancer originating in blood-forming tissues like bone marrow, causes the overproduction of abnormal white blood cells, which disrupt normal blood cell function. The rise in leukemia cases is linked to factors such as an aging population, environmental exposures, genetic predispositions, and improved diagnostic capabilities. Blincyto plays a critical role in treating leukemia as a bispecific T-cell engager, helping the immune system target and eliminate leukemia cells, especially in patients with acute lymphoblastic leukemia (ALL). For example, in January 2024, the American Cancer Society projected approximately 62,770 new leukemia cases in the United States in 2024, an increase from 59,610 in 2023. As a result, the rising incidence of leukemia is fueling the growth of the Blincyto market.
An increase in healthcare spending is expected to support the growth of the Blincyto market. Healthcare spending encompasses all expenditures on health services and goods, including personal care, public health programs, and health administration. This spending is rising due to factors such as population growth, aging demographics, rising service costs, higher chronic illness prevalence, and advancements in medical technology. The rise in healthcare spending improves access to advanced cancer treatments like Blincyto, facilitating wider adoption and better patient outcomes. For instance, in May 2024, a report from the Office for National Statistics in the UK revealed that healthcare expenditure in the UK reached around $363 billion in 2023, representing a 5.6% increase from the previous year, well above the 0.9% increase in 2022. Consequently, higher healthcare spending is driving the Blincyto market.
A key trend in the Blincyto market is the focus on developing innovative therapies, including immuno-oncology treatments, to target and destroy cancer cells. Immuno-oncology therapies use the body's immune system to recognize and eliminate cancer cells. For example, in June 2024, Amgen Inc., a U.S.-based biotechnology company, received FDA approval for Blincyto (blinatumomab) to treat CD19-positive Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia (B-ALL) in both adult and pediatric patients, regardless of the presence of measurable residual disease (MRD). Blincyto is a bispecific T-cell engager (BiTE) that binds to CD19 on B-cell tumors and CD3 on T-cells, guiding T-cells to target and destroy cancer cells.
Key player operating in the blincyto market is Amgen Inc.
North America was the largest region in the Blincyto market in 2024. Asia Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in blincyto report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the blincyto market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The blincyto market consists of sales of oncology medications, biosimilars, immunotherapy drugs, anti-inflammatory medications and hematology medications. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Blincyto Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on blincyto market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Where is the largest and fastest growing market for blincyto ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The blincyto market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.